PICO IV and Liquivida partner to advance sterile CBD delivery in IV therapy, appoint Sam Tejada as brand spokesperson

PICO IV, the company behind the world’s first sterile cannabidiol (CBD) emulsion, has entered a strategic partnership with Liquivida, a national leader in IV therapy and wellness services. The move aims to accelerate the adoption of sterile CBD in clinical and wellness settings, expand patient education on the body’s endocannabinoid system (ECS), and strengthen both companies’ leadership positions in the evolving IV hydration market. As part of the collaboration, Liquivida founder Sam Tejada—who also chairs the Leadership Advisory Board for the American IV Association (AIVA)—has joined PICO IV’s Advisory Board and will serve as a spokesperson for the brand.

Tejada emphasized that the partnership is not merely about product adoption but about redefining a category. “This isn’t just a new product—it’s the beginning of a new category of treatment,” he said. “At Liquivida, we’re deeply selective about what we bring into our clinics, and PICO IV meets the highest standards of safety, science, and purpose. We’re excited about what this means for the future of IV therapy and the health of our patients.”

How the PICO IV–Liquivida partnership could reshape CBD delivery

While CBD has become mainstream since the 2018 U.S. Farm Bill legalized hemp-derived cannabinoids, oral and topical forms remain the dominant delivery methods. These approaches, however, are hindered by low bioavailability—often less than 20% of the CBD content reaches systemic circulation. PICO IV’s patent-pending technology reduces CBD particle size to the pico realm—smaller than nano—enabling sterile filtration and near-complete bioavailability approaching 100%. This ultra-fine particle size facilitates rapid systemic absorption, enabling more precise dosing and faster onset of effects, a significant advantage for clinical applications such as pain management, anxiety reduction, and performance recovery.

Unlike existing CBD products, PICO IV is the first and only CBD formulation to achieve sterile status, manufactured in a current Good Manufacturing Practice (cGMP) facility, subjected to rigorous batch testing, and sterilized using electron beam (e-beam) technology. This sterilization method is known for eliminating microbial contaminants without degrading the compound, ensuring product integrity and patient safety.

PICO IV CEO Joe Young said the company’s guiding principle is uncompromising safety. “With our sterile CBD being so new to the market, we understand the opportunity ahead of us,” he noted. “Our top priority has always been safety. We’ve taken extraordinary care to ensure this product can be trusted throughout every step in our manufacturing process.”

Why interest in advanced IV wellness is surging

The timing of the PICO IV–Liquivida partnership coincides with a global surge in demand for functional wellness services. IV hydration therapy, once confined to hospitals, is now widely offered in wellness clinics, concierge medical practices, and mobile services. Patients seek treatments for hydration, immune support, recovery, and energy enhancement—often incorporating vitamins, minerals, amino acids, and now, potentially, sterile CBD.

The global IV hydration therapy market is projected to reach USD 4.4 billion by 2029, growing at a CAGR of 9.6% from USD 3.05 billion in 2025. In the U.S. alone, mobile IV hydration services—valued at USD 568 million in 2024—are forecast to nearly triple to USD 1.56 billion by 2034. The broader infusion therapy market, which includes IV wellness, is already a USD 38.9 billion industry and is projected to more than double by 2034.

CBD adoption is also on a steep upward trajectory. The global CBD consumer health market is expected to hit USD 23.94 billion in 2025 and reach USD 77.48 billion by 2034, representing a CAGR of 14.01%. This creates a substantial addressable market for innovations like PICO IV’s sterile emulsion, particularly if clinical validation supports its efficacy.

Raising awareness of the endocannabinoid system in mainstream medicine

A core component of the partnership is provider education on the ECS—a complex cell-signaling system that regulates mood, immune function, pain perception, and homeostasis. While the ECS has been studied since the 1990s, it remains largely absent from conventional medical training. Liquivida’s nationwide network of affiliate physicians will integrate educational modules and clinical guidance on ECS function, CBD science, and safe administration protocols for sterile CBD.

For Liquivida, the initiative strengthens its position as a science-forward wellness brand in a sector where patient trust and regulatory scrutiny are critical. For PICO IV, aligning with a recognized national provider network accelerates market entry while ensuring the product is used in accordance with best-practice clinical standards.

Competitive positioning in a fast-growing sector

The CBD delivery market is increasingly crowded, with companies offering oils, tinctures, edibles, and nano-emulsions. However, PICO IV’s sterile CBD emulsion occupies a unique niche that competitors have yet to match. This first-mover advantage could be significant in establishing long-term clinical partnerships, securing premium pricing, and protecting intellectual property through patents.

In IV therapy, competition is intensifying as wellness clinics, med spas, and mobile providers race to differentiate their offerings. Adding sterile CBD infusions could provide Liquivida and its affiliates with a high-margin, differentiated service that appeals to both wellness enthusiasts and patients seeking evidence-based, plant-derived therapies.

From an investor perspective, the partnership aligns two growth-oriented sectors—CBD and IV wellness—that have complementary customer bases and distribution models. If adoption rates follow the trajectory of other high-bioavailability innovations, revenue streams could expand rapidly over the next five years.

Industry sentiment and potential adoption curve

Early industry reactions to the announcement have centered on the pairing of two brands with strong reputations in their respective spaces. Analysts note that CBD’s integration into IV therapy is a logical extension of existing wellness protocols, especially given patient interest in multi-compound infusion blends. However, adoption will depend heavily on provider confidence, regulatory clarity, and peer-reviewed clinical data.

Institutional investors tracking wellness-tech convergence trends see the move as an example of functional medicine and natural therapeutics finding common ground with clinical delivery methods. While CBD companies have often faced market volatility due to shifting regulations and consumer perceptions, partnerships that emphasize medical-grade manufacturing and clinical oversight are viewed as lower-risk plays.

How PICO IV plans to scale sterile CBD adoption

Scaling will require targeted provider outreach, inclusion in medical conferences, and robust educational campaigns. PICO IV’s Advisory Board, now strengthened by Tejada’s appointment, is expected to guide market expansion strategy and help bridge conversations between the wellness and medical communities.

Liquivida’s national footprint offers immediate access to a multi-state clinic network, plus a mobile IV therapy arm capable of delivering services in high-demand metropolitan markets. By leveraging both in-clinic and on-demand delivery models, the partnership could rapidly gather patient outcome data—valuable for both marketing and clinical validation.

What this means for the future of IV therapy and CBD

The partnership’s potential impact extends beyond revenue growth for the two companies. If sterile CBD infusions gain traction, it could open a new therapeutic category within IV therapy—one with applications in sports medicine, pain management, mental health support, and chronic illness care.

Analysts suggest that a successful rollout could trigger similar collaborations between CBD innovators and large-scale IV providers, accelerating product standardization and insurance recognition over the next decade. For now, the PICO IV–Liquivida alliance will serve as a test case for whether sterile CBD can move from niche innovation to mainstream wellness protocol.